Division of Infectious Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Orlando Immunology Center, Orlando, Florida.
AIDS. 2018 Jul 31;32(12):1723-1725. doi: 10.1097/QAD.0000000000001894.
: A phase 2, randomized, active-controlled study of initial antiretroviral therapy with bictegravir or dolutegravir in combination with emtricitabine and tenofovir alafenamide showed excellent efficacy. After 60 weeks of blinded treatment, participants switched to a single-tablet regimen of bictegravir, emtricitabine, and tenofovir alafenamide. Switching maintained viral suppression in all participants who remained on the study through 12 weeks in the open-label phase, and was safe and well tolerated.
一项关于比克替拉韦或多替拉韦联合恩曲他滨和替诺福韦艾拉酚胺作为初始抗逆转录病毒治疗的 2 期、随机、阳性对照研究显示出了极好的疗效。在盲法治疗 60 周后，参与者转为服用比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺单片复方制剂。在开放标签期的 12 周内，所有继续参与研究的参与者均维持病毒抑制，且转换是安全且耐受良好的。
